MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.